<DOC>
	<DOCNO>NCT00708162</DOCNO>
	<brief_summary>The purpose study compare safety , tolerability efficacy regimen contain once-daily elvitegravir ( EVG ) versus twice-daily raltegravir ( RAL ) add background regimen ( 1 fully-active ritonavir ( RTV ) -boosted protease inhibitor ( PI ) plus 1 2 additional antiretroviral ( ARV ) agent ) HIV-1 infect , ARV treatment-experienced adult document resistance , least six month experience prior screen two different class ARV agent . Participants randomize 1:1 ratio receive EVG plus background regimen ( Elvitegravir group ) , raltegravir plus background regimen ( Raltegravir group ) . Due know drug interaction , participant Elvitegravir group receive RTV-boosted atazanavir ( ATV ) RTV-boosted lopinavir ( LPV ) part background regimen receive elvitegravir low dose ( 85 mg ) .</brief_summary>
	<brief_title>Multicenter , Randomized , Double-Blind , Double-Dummy , Phase 3 Study Safety Efficacy Elvitegravir Versus Raltegravir</brief_title>
	<detailed_description>The background regimen construct investigator base viral resistance testing . The fully active PI define phenotypic resistance analysis . For phenotypic susceptibility , fully active define low clinical biological cutoff . Participants require take ritonavir dose base dose schedule indicate prescribe information PI ; additional ritonavir require take EVG . No market PIs allow part background regimen due unknown drug interaction . The second agent one nucleoside nucleotide reverse transcriptase inhibitor ( NRTI ) , etravirine , maraviroc , T-20 . However , second agent must include integrase inhibitor ; nonnucleoside reverse transcriptase inhibitor efavirenz , nevirapine , delavirdine ( due unknown drug interaction ) ; fixed-dose combination therapy Atripla® Trizivir® ( abacavir sulfate/lamivudine/zidovudine ) . The second agent may may fully active ( except Spain , participant receive fully active second agent , request Spanish regulatory agency ) . If M184V/I reverse transcriptase ( RT ) mutation present screen genotype report NRTI use second agent , either FTC LAM may add third agent background regimen maintain M184V/I mutation . In situation , fixed-dose combination therapy Combivir® , Truvada® , Epzicom/Kivexa® may prescribe combined second third agent background regimen . After Week 96 , participant continue take blind study drug attend visit treatment assignment unblinded , point give option participate open-label EVG extension phase study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Plasma HIV1 RNA level ≥ 1,000 copies/mL screening Documented resistance least six month experience prior screen two different class antiretroviral agent Stable antiretroviral regimen least 30 day prior screen : however , participant may discontinue antiretroviral regimen screen remain therapy baseline discretion investigator Eligible receive one fullyactive ritonavirboostedPIs , allow second agent Normal ECG Adequate renal function ( estimate glomerular filtration rate accord CockcroftGault formula ≥ 60 mL/min ) Hepatic transaminases ≤ 5 × upper limit normal Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function ( absolute neutrophil count ≥ 1,000/mm^3 ; platelet ≥ 50,000/mm^3 ; hemoglobin ≥ 8.5 g/dL ) Serum amylase &lt; 1.5 × upper limit normal range Negative serum pregnancy test ( female childbearing potential ) Males females childbearing potential must agree use highly effective contraception method Age ≥ 18 year Life expectancy ≥ 1 year Ability understand sign write informed consent form New AIDSdefining condition diagnose within 30 day prior screen Prior treatment HIV1 integrase inhibitor Participants experience ascites Participants experience encephalopathy Females breastfeed Positive serum pregnancy test time study ( female childbearing potential ) Participants receive ongoing therapy disallow medication Current alcohol substance use judge investigator potentially interfere study compliance Malignancy cutaneous Kaposi 's sarcoma basal cell carcinoma Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline Participation clinical trial ( except etravirine maraviroc expand access program ) , without prior approval sponsor Any clinical condition prior therapy would make participant unsuitable study Known hypersensitivity study drug , metabolites formulation excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV I</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>